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Edited by Judit Ova´diAbstract The arylamine N-acetyltransferases (NAT; EC
2.3.1.5) are xenobiotic-metabolizing enzymes (XME) that cata-
lyze the transfer of an acetyl group from acetylCoA (Ac-CoA)
to arylamine, hydrazines and their N-hydroxylated metabolites.
Eukaryotes may have up to three NAT isoforms, butMesorhizo-
bium loti is the only prokaryote with two functional NAT isoforms
(MLNAT1 and MLNAT2). The three-dimensional structure of
MLNAT1 has been determined (Holton, S.J., Dairou, J., Sandy,
J., Rodrigues-Lima, F., Dupret, J.M., Noble, M.E.M. and Sim,
E. (2005) Structure of Mesorhizobium loti arylamine N-acetyl-
transferase 1. Acta Cryst, F61, 14–16). No MLNAT2 crystals
have yet been produced, despite the production of suﬃcient quan-
tities of pure protein. Using puriﬁed recombinant MLNAT1 and
MLNAT2, we showed here that MLNAT1 was intrinsically more
stable than MLNAT2. To test whether diﬀerent structural fea-
tures could explain these diﬀerences in intrinsic stability, we con-
structed a high-quality homology model for MLNAT2 based on
farUV-CDdata.Despite low levels of sequence identity with other
prokaryotic NAT enzymes (28% identity), this model suggests
that MLNAT2 adopts the characteristic three-domain NAT fold.
More importantly, molecular dynamics simulations on the
structures of MLNAT1 and MLNAT2 suggested that MLNAT2
was less stable than MLNAT1 due to diﬀerences in amino-acid
sequence/structure features in the a/b lid domain.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Arylamine N-acetyltransferases (NAT; EC 2.3.1.5) are xeno-
biotic-metabolizing enzymes (XME). They catalyze the transfer
of an acetyl group from acetylCoA (Ac-CoA) to the nitrogen orAbbreviations: NAT, arylamine N-acetyltransferase; M. loti, Meso-
rhizobium loti; RMSD, root mean square deviation; RMSF, root mean
square ﬂuctuation
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doi:10.1016/j.febslet.2006.02.033oxygen atom of arylamines, hydrazines, and their N-hydroxyl-
ated metabolites [1]. These XME therefore play a key role
in the detoxiﬁcation and metabolic activation of numerous
xenobiotics.
NAT and NAT-like enzymes have been identiﬁed and char-
acterized in several vertebrate species, including human,
mouse, rat, rabbit, hamster and chicken [2–8]. NAT enzymes
have also been identiﬁed more recently in a range of prokary-
otes including Salmonella typhimurium, Mycobacterium
smegmatis, Mycobacterium tuberculosis, Pseudomonas aerugin-
osa and Mesorhizobium loti [9–11]. In prokaryotes, NAT may
be involved in antibiotic resistance [12] and in the synthesis of
complex lipids [13]. To date, X-ray crystallographic structures
have been reported for four NAT orthologs from Salmonella
typhimurium (STNAT), Mycobacterium smegmatis (MSNAT),
Pseudomonas aeruginosa (PANAT) and Mesorhizobium loti
(MLNAT1) [14–17]. All these structures contain a highly con-
served three-domain fold (an N-terminal helical bundle, a cen-
tral b-barrel and a C-terminal a/b lid) and a cysteine protease-
like (Cys-His-Asp) catalytic triad thought to catalyze substrate
acetylation [17]. Based on these prokaryotic NAT structures,
three-dimensional models of the catalytic domain of human
NAT1 and NAT2 isoforms have also been proposed [18,19].
Unlike eukaryotic organisms, which have up to three NAT
isoforms, no prokaryote has yet been shown to possess more
than one functional NAT enzyme [11,20]. However, bioinfor-
matics analysis of the genome of M. loti, a nitrogen-ﬁxing rhi-
zobacterium that lives in symbiosis with leguminous plants
[21,22], revealed the presence of genes encoding two NAT iso-
forms, MLNAT1 and MLNAT2, making M. loti the ﬁrst
example of a eubacterial species with two putative NAT iso-
forms [11]. The very recent cloning and biochemical character-
ization of these two enzymes conﬁrmed that MLNAT1 and
MLNAT2 are indeed the ﬁrst functional NAT paralogs to be
identiﬁed in a prokaryotic organism [23]. Sequence analyses
showed the percentage identity between the M. loti NAT iso-
forms (27%) to be lower than that between isoforms in any
eukaryotic species (67–94%) (Table 1) [11]. This unusually
low level of identity between two paralogous NAT enzymes
may reﬂect divergent functions and putative conformational
diﬀerences [17]. Although no speciﬁc function has yet been as-
signed to MLNAT1 and MLNAT2 [23], the three-dimensionalblished by Elsevier B.V. All rights reserved.
Table 1
Amino-acid identity between NAT isoforms from diﬀerent species
Species Number of
isoforms
% amino acid identity
between isoforms
Homo sapiens 2 81%
Rattus norvegicus 2 82%
Mesocricetus auratus 2 79%
Mus musculus 3 65% NAT1/NAT2 81%
NAT1/NAT3 67%
NAT2/NAT3 73%
Gallus gallus 3 51% NAT1/NAT2 64%
NAT1/NAT3 60%
NAT2/NAT3 60%
Mesorhizobium loti 2 27%
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common fold reported for other NAT structures. Conversely,
although suﬃcient amounts of pure recombinant MLNAT2
can be obtained for crystallization trials, no crystal has yet
been obtained due to the instability and aggregation of the
protein [17,23].
Here, we analyzed the intrinsic stability of the puriﬁed re-
combinant MLNAT1 and MLNAT2 enzymes by determina-
tion of the ﬁrst-order heat inactivation constant. We showed
that MLNAT2 is intrinsically less stable than MLNAT1. This
may partially account for diﬃculties in crystallizing the
MLNAT2 isoform. To test whether diﬀerent structural proper-
ties between MLNAT1 and MLNAT2 could contribute to
their diﬀerent intrinsic stability, we constructed a high-quality
structure model for MLNAT2, based on far UV-CD data, sec-
ondary structure predictions and computational homology
modeling. This model suggest that, despite the low level of se-
quence identity with other prokaryotic NAT enzymes,
MLNAT2 adopts the characteristic three-domain NAT fold.
Further sequence-based bioinformatics analyses and molecular
dynamics simulations suggested that the C-terminal a/b lid do-
main of MLNAT2 probably makes a major contribution to
the greater instability of this NAT isoform.
As several major aniline-derived soil pollutants are sub-
strates of MLNAT2 [23], the structural model described here
may also provide insight into the role of the N-acetylation
pathway in pollutant biotransformation.2. Materials and methods
2.1. Materials
The Bradford protein assay kit was supplied by BioRad (France). P-
aminosalicylic acid (PAS), acetyl-coenzyme A (AcCoA), 5,5 0-dithio-bis
2-nitrobenzoic acid (DTNB or Ellman’s reagent) and HIS-Select Nick-
el resin were obtained from Sigma (France).
2.2. Protein production and puriﬁcation
E. coli BL21 (DE3) cells containing pET-28A-based plasmids encod-
ing MLNAT1 or MLNAT2 were used for the production and puriﬁca-
tion of the corresponding recombinant enzymes, as previously
described [23]. Brieﬂy, transformed bacteria were induced with
0.5 mM isopropyl-1-thio-b-D-galactopyranoside, cultured for 5 h at
37 C (20 C for MLNAT2) and incubated overnight at 4 C. Bacteria
from a 1 l culture were harvested by centrifugation (6000 · g, 30 min)
and washed with PBS (phosphate-buﬀered saline). The bacterial pellet
(6000 · g, 30 min) was resuspended in 20 ml of PBS supplemented with
lysozyme (1 mg/ml ﬁnal concentration) and protease inhibitors. Thesuspension was incubated for 1 h at 4 C. We then added protease
inhibitors and 0.1% Triton X-100 (ﬁnal concentration) and incubated
the suspension for a further 1 h at 4 C. The lysate was then subjected
to sonication on ice (ﬁve pulses of 10 s each) and centrifuged
(12000 · g, 30 min). The supernatant was incubated with 1.5 ml of
HIS-Select Nickel resin (in the presence of 20 mM imidazole) for 2 h
at 4 C. The resin was then poured into a column and washed succes-
sively with lysis buﬀer supplemented with 0.1% Triton X-100 and PBS
(in the presence of 50 mM imidazole). Recombinant MLNAT1 and
MLNAT2 were eluted with 300 mM imidazole in PBS. Puriﬁed en-
zymes were reduced by incubation with 10 mM DTT for 10 min at
4 C and dialyzed against 25 mM Tris–HCl, pH 7.5, 1 mM EDTA.
Purity was assessed by SDS–PAGE and protein concentrations were
determined with a standard Bradford assay.
2.3. Enzyme assay and determination of ﬁrst-order heat inactivation
constants (kinact)
The activity of MLNAT1 and MLNAT2 was assayed by measuring
the rate of hydrolysis of acetyl-CoA (ﬁrst substrate) in the presence of
PAS (arylamine substrate), using 5,5 0-dithiobis 2-nitrobenzoic acid
(DTNB or Ellman’s reagent) as previously described [24]. Brieﬂy, we
mixed PAS (500 lM ﬁnal concentration) and samples containing puri-
ﬁed enzymes in 25 mMTris–HCl, pH 7.5, 1 mMEDTAbuﬀer and incu-
bated the mixture for 5 min at 37 C in a 96-well ELISA plate. AcCoA
was added to a ﬁnal concentration of 400 lM to start the reaction, in a
total volume of 100 ll (reaction temperature 37 C). The reaction was
quenched by adding 25 ll of 5 mM DTNB in guanidine hydrochloride
solution (6.4 M guanidine-HCl, 0.1 M Tris–HCl, pH 7.3). Absorbance
wasmeasured at 405 nm, using anELISAplate analyzer. All assayswere
performed in triplicate, under conditions in which the reaction rate plot
was initially linear. The controls consisted of reactions carried out in the
absence of enzyme,AcCoAorPAS.The amount ofCoAproduced in the
reaction was determined by comparison with a standard curve obtained
with DTNB. Data are expressed as means ± S.D.
The intrinsic stability of puriﬁed MLNAT1 and MLNAT2 was
determined as previously described [25]. Brieﬂy, puriﬁed MLNAT1
and MLNAT2 (50 lg/ml ﬁnal) were incubated at 50 C. At selected
time points, aliquots were removed and assayed for PAS-dependent
N-acetyltransferase activity, as described above. The ﬁrst-order heat
inactivation constants (kinact) for MLNAT1 and MLNAT2 were deter-
mined by plotting ln % residual activity versus time.
2.4. Far ultra-violet circular dichroism (Far UV-CD)
Puriﬁed MLNAT1 (0.58 mg/ml) and MLNAT2 (0.43 mg/ml) protein
samples were dialyzed against 10 mM sodium phosphate, pH 7 and
used for circular dichroism (CD). CD measurements were acquired
with an Aviv 215 spectropolarimeter (AvivBiomedical, USA), using
a cylindrical cells with a 0.2 mm path length. Signal-to-noise ratio
was optimized by averaging ﬁve individual CD spectra acquired with
a constant 0.5 nm step and for two adjacent wavelength ranges with
diﬀerent integration times: 1 s from 260 to 200.5 nm, and 4 s from
200 to 180 nm. All spectra were corrected by subtracting the corre-
sponding baseline, acquired with the dialysis buﬀer under the same
conditions. The resulting corrected CD intensities were then converted
to De per residue. Quantitative analysis of CD spectra were carried out
with the CDSSTR routine included in the CDPro package ([26]; http://
lamar.colostate.edu/~sreeram/CDPro/main.html).
2.5. Sequence alignment, secondary structure analysis and protein
instability index determination
Clustal W1.8 [27] was used to align NAT enzyme sequences, using
the Dayhoﬀ PAM matrix. The PSI-Pred algorithm was used to predict
secondary structures [28]. Secondary structures were determined from
Protein Databank (PDB) coordinates, using the DSSP algorithm [29].
The protein instability index was determined with the Guruprasad
algorithm [30]. Protein sequences with an instability index below 40
are predicted to be stable, whereas proteins with an instability index
above 40 are predicted to be unstable [30].2.6. Homology modeling, structural analysis and molecular dynamics
The three-dimensional model of MLNAT2 was constructed by com-
parative modeling with the MODELLER 7 program [31]. The struc-
tures of MLNAT1 (pdb entry:2BSZ), MSNAT (pdb entry:1GX3)
Fig. 1. SDS–PAGE analysis of recombinant MLNAT1 and
MLNAT2. We subjected 2 lg of puriﬁed enzyme to SDS–PAGE
under reducing conditions and stained the gel with Coomassie blue
(MLNAT1: lane 1; MLNAT2: lane 2).
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used for homology modeling was improved manually, taking into ac-
count the predicted secondary structure of MLNAT2 and the second-
ary structures of the templates. One hundred models were generated
and their quality assessed using the Modeller Objective Function
parameter; the best model was retained and the side chains were repo-
sitioned in optimized conformations, using SCWRL [32]. The
MLNAT2 model was ﬁnally subjected to energy minimization, using
the Gromos 96 force ﬁeld implemented in GROMACS version 3.2.1
[33]. The minimized MLNAT2 model presented here was compatible
with the CD experiments in terms of secondary structure and satisﬁed
all the PROCHECK [34] stereochemical veriﬁcations. Structures were
analyzed and visualized with DeepView 3.7b [35] and Pymol (Delano
Scientiﬁ LLC, USA). Poisson–Boltzmann electrostatic potential repre-
sentations were generated with DeepView 3.7b [35].
For molecular dynamics simulations, the MLNAT1 structure (pdb
entry: 2BSZ) and the MLNAT2 model were simulated as immersed
in a box of 14374 (13390) SPC water molecules (14 A˚-thick layer
of water, with a box size of 78 A˚ · 76 A˚ · 82 A˚ (76 · 77 · 76)). Na+
counter ions were added to neutralize the system (4 ions for the
wild-type/3 ions for the model). Calculations were carried out with
Gromacs 3.2.1, using the Gromos force ﬁeld [33] under periodic
boundary conditions. An electrostatic twin-range cutoﬀ of 14/18 A˚
was employed. The van der Waals cutoﬀ was 14 A˚. The energy of
the system was minimized over about 1000 cycles, using then steepest
descent algorithm followed by heating to 300 K. During heating, har-
monic restraints were imposed on the atomic positions of the protein
and counterions. After an equilibration period of 10 ps at 300 K, these
restraints were slowly relaxed over a period of 100 ps until a free sys-
tem was achieved. The simulation was performed under NVT condi-
tions, coupling the system to a heat bath, using the Berendsen
algorithm [36]. All bond lengths were constrained using the LINCS
algorithm [36] and a time step for integration of 2 fs. From this
100 ps equilibration phase, the wild-type monomer was moved through
a 2 ns trajectory to reach 2.1 ns. Conformations resulting from the pro-
duction phase of each simulation were stored at intervals of 1 ps and
analyzed (2000 conformations). We calculated global properties for
the overall conformations of the MLNAT1 and MLNAT2 proteins,
including root mean square deviation (RMSD), root mean square ﬂuc-
tuation (RMSF), and secondary structures, along the trajectory.Fig. 2. Determination of ﬁrst-order heat inactivation constants (kinact)
for MLNAT1 and MLNAT2. We used the method of Fretland et al.
[25] to determine kinact constants. The values of kinact obtained were
0.015 min1 for MLNAT1 (black triangles) and 0.12 min1 for
MLNAT2 (black circles).3. Results and discussion
3.1. Recombinant protein puriﬁcation and ﬁrst-order heat
inactivation constants
MLNAT1 and MLNAT2 enzymes are the ﬁrst functional
paralogous NAT enzymes to be identiﬁed in a prokaryote
[11,17,23]. Unlike the NAT paralogs found in other species,
MLNAT1 and MLNAT2 displayed only moderate (27%) se-
quence identity (Table 1). Furthermore, whereas the MLNAT1
structure was readily determined by X-ray crystallography, the
puriﬁed recombinant MLNAT2 enzyme proved diﬃcult to
crystallize. Preliminary studies also suggested that, with the
exception of the N-terminal active-site core domain, there were
no extensive regions of residue conservation between the M.
loti NAT paralogs. We further investigated the structure of
MLNAT2 by producing the two M. loti NAT enzymes in
E. coli and purifying them as N-terminal histidine-tagged pro-
teins, as recently described [23]. Both MLNAT1 and
MLNAT2 were puriﬁed to apparent homogeneity by Ni2+
ion aﬃnity chromatography (Fig. 1). Typically, we obtained
more than 30 mg of MLNAT1 per liter of bacterial culture.
For MLNAT2, protein production was induced at a lower
temperature (20 C rather than 37 C), to prevent proteolysis.
We generally obtained 15 mg of MLNAT2 per liter of culture.
Both puriﬁed enzymes were active, as they N-acetylated several
prototypic NAT substrates (data not shown and [23]). Interest-
ingly, whereas the recombinant MLNAT1 protein was stablefor days at 4 C, MLNAT2 displayed aggregation and a loss
of activity in the same conditions (data not shown). Diﬀerences
in protein stability have been reported for other NAT para-
logs. Indeed, Dupret et al. [37] reported that human NAT2
is 10 times more stable than human NAT1. Similar results were
also reported by Hein and colleagues [25,38]. We assessed the
intrinsic stability of MLNAT1 and MLNAT2 as described by
Fretland et al. [25,38]. MLNAT2 was found to have a kinact of
0.12 min1 whereas MLNAT1 had a kinact of 0.015 min
1
(Fig. 2). These values are in the same range as those reported
for the human NAT1 and NAT2 paralogues [25,38]. They con-
ﬁrm the lower intrinsic stability of MLNAT2 (MLNAT1 was
eight times more stable) and may therefore account for the ob-
served lower stability of MLNAT2 during puriﬁcation and dif-
ﬁculties in producing MLNAT2 crystals.
3.2. Far UV-CD spectroscopy, homology-modeling and
structural analysis of the MLNAT2 model
We circumvented the lack of a crystallographic structure for
MLNAT2 by combining a secondary structure analysis for
MLNAT1 and MLNAT2 with far UV-CD and computational
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structure. The secondary structures of the two recombinant en-
zymes were compared by quantitative decomposition of their
far-UV CD spectra. The overall far-UV CD spectra of
MLNAT1 and MLNAT2 were similar, with only small diﬀer-
ences in b-structures and coil content (Fig. 3). The recon-
structed spectra, deduced from CDSSTR analysis [26] ﬁtted
the experimental data well (Fig. 3). CDSSTR analyses indi-
cated that the a-helix contents of the two enzymes were not sig-
niﬁcantly diﬀerent (29 ± 1% and 30 ± 1% for MLNAT1 and
MLNAT2, respectively) but revealed small diﬀerences in the
b-strand contents (22% ± 2 and 19% ± 2 b-strand for
MLNAT1 and MLNAT2, respectively). The percentages of
a-helix and b-strand obtained for MLNAT2 were also similar
to those deduced from the structures of other NAT enzymes
(data not shown). In addition, the percentages of a-helix and
b-strand obtained for MLNAT1 were consistent with data de-Fig. 3. Analysis of MLNAT1 and MLNAT2 secondary structures by far U
Section 2. Normalized spectra of MLNAT1 and MLNAT2 are depicted using
spectra reconstructed from the best ﬁts with CDSSTR analysis [26].
Fig. 4. Multiple alignment of MLNAT2 with MLNAT1, MSNAT and STN
alignment was further improved by taking into account the secondary structur
structures extracted from the PDB ﬁles of MLNAT1, MSNAT and STNAT (
[17] are depicted above the MLNAT1 sequence (black: helical bundle; medium
residues.duced from the crystal structure of the enzyme (PDB entry:
2BSZ). Further analysis of the secondary structure of
MLNAT2, using the PSI-Pred algorithm, also gave results
highly consistent with far UV-CD data (data not shown).
PSI-Pred results also suggested that the secondary structure
topology of MLNAT2 was very similar to that obtained by
crystallography of NAT enzymes (data not shown).
We used the MODELLER 7 package to construct a struc-
tural model of MLNAT2, using the structures of MSNAT,
STNAT and MLNAT1 as templates. The secondary structure
of MLNAT2 predicted by PSI-Pred was used for manual
improvement of the Clustal W sequence alignment of
MLNAT2 with the other three NAT sequences (Fig. 4). The
10 best models generated by MODELLER (those with the
lowest Modeller Objective Function) were analyzed with the
PROCHECK validation package and their secondary struc-
ture content was compared with the far UV-CD data. The ﬁnalV-CD. The spectra were recorded under the conditions described in
closed and open circles, respectively. The solid lines correspond to the
AT. Amino acid sequences were aligned, using Clustal W1.8 [27]. The
es predicted for MLNAT2 (PSI-Pred algorithm [28]) and the secondary
DSSP algorithmn [29]). The three structural domains of NAT enzymes
gray: b-barrel; light gray:a/b lid). Black circles indicate catalytic triad
Fig. 5. Structural model of MLNAT2. (A) Structural alignment of the MLNAT2 model, obtained by homology modeling with MLNAT1.
Secondary structures extracted by DSSP are shown for each enzyme. Catalytic triad residues are indicated by a black circle. Conserved residues are
shaded in black. (B) Ribbon representation of the crystal structure of MLNAT1, MLNAT2 homology model and structural alignment. a-Helix and
b-strands are in red and yellow, respectively.
Fig. 6. Electrostatic potential analysis. MLNAT1, MLNAT2, STNAT, MSNAT and PANAT structures were aligned and Poisson–Boltzmann
electrostatic calculations carried out with Deep-View 3.7b [35]. Blue and red colors indicate positive and negative electrostatic potential, respectively.
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Fig. 7. Comparison of RMSF of the Ca atoms of MLNAT1 and MLNAT2 over the molecular dynamics simulations (2 ns). Molecular dynamics
simulations of MLNAT1 and MLNAT2 structures were carried out as described in Section 2. Variations of the spatial position of each Ca over the
dynamics simulation (RMSF in A˚) are shown for MLNAT1 (upper panel) and MLNAT2 (lower panel). Root mean square deviation (RMSD) of the
Ca atoms of MLNAT1 and MLNAT2 as a function of time (ps), over the simulations, is shown in the insets.
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ondary structures consistent with the results of far UV-CD
experiments and satisﬁed all the PROCHECK stereochemical
veriﬁcations. Indeed, 87% of the residues were in the most fa-
vored regions of the Ramachandran plot. No residue was pres-
ent in the disallowed region. The overall quality G-factor was
0.13, indicating that the MLNAT2 model is of high stereo-
chemical quality. Comparison of the structural model for
MLNAT2 with the structures of other NAT enzymes, includ-
ing MLNAT1 (Fig. 5), indicated that despite the low level of
sequence identity, MLNAT2 shares an almost identical fold
with MLNAT1, MSNAT, STNAT and PANAT. Fig. 5 shows
a cartoon view of MLNAT1 and MLNAT2 and their struc-
tural alignment. Structural alignment of the a-carbons of
MLNAT2 with those of MLNAT1, MSNAT and STNAT
gave a RMSD (root mean square deviation) of 1.2, 1.3 and
0.7 A˚, respectively (over 240 equivalent residues). These re-
sults suggest that the structure of MLNAT2 is similar to that
of the other known NATs [14–17]. As for the other NAT struc-
tures, MLNAT2 may be divided into three domains of approx-
imately equal size (Fig. 5). The ﬁrst two domains, a helical
bundle and a b-barrel, are aligned such that three residues
(Cys68, His105, Asp120) form a catalytic triad. Minor diﬀer-
ences between MLNAT2 and other NAT structures, including
MLNAT1 in particular (Fig. 5), result mainly from single-res-
idue insertions/deletions accommodated in loop regions, and
from mobile loop regions linking more stable secondary struc-Fig. 8. Comparison of the Ca RMSD variations of the three structural doma
bundle, b-barrel and a/b lid domains of MLNAT1 (black lines) and MLNA
(2000 ps).ture elements [17]. Most of the diﬀerences between the struc-
tures of the MLNAT1 and MLNAT2 paralogs were in the
a//b lid domain (Figs. 5 and 6) (starting at the end of b9). This
domain has already been shown to account for a substantial
part of the diﬀerences between NAT structures from diﬀerent
species [15,17]. The a/b lid domain is known to be ﬂexible
and to be involved in arylamine substrate binding [15,17]. In
addition, it has been shown that this C-terminal domain con-
tains structural determinants involved in the intrinsic stability
of NAT enzymes [37,39]. The small diﬀerences observed be-
tween the a/b lid domain of MLNAT2 and MLNAT1 enzymes
were further supported by electrostatic potential calculations.
Fig. 6 shows surface proﬁles and electrostatic potentials for
the four known NAT crystallographic structures and the
MLNAT2 model. Consistent with the data reported by Sandy
et al. [40], the active-site cleft of the NAT enzymes observed on
crystallography appeared to have a negative electrostatic po-
tential. In addition, whereas the a/b lid domain of MLNAT1,
STNAT, MSNAT and PANAT also appeared to have a nega-
tive electrostatic potential, this domain seemed to be more
positively charged in MLNAT2. These data suggest that the
C-terminal a/b lid domain of MLNAT2 may behave diﬀerently
from the equivalent domains in other NAT structures. Inter-
estingly, protein instability index, calculated with the Gurupra-
sad algorithm [30], suggested that MLNAT2 (instability index
of 47.5) was unstable whereas the other NAT enzymes
(MLNAT1, MSNAT, STNAT, and PANAT; instability indi-ins of MLNAT1 and MLNAT2. The RMSF of the Ca atoms of the a-
T2 (dashed lines) are shown over the molecular dynamics simulations
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the MLNAT2 protein was mainly due to the C-terminal a/b
lid domain (data not shown). These data suggest that
MLNAT2 may be less stable than MLNAT1 at least partly
due to its C-terminal a/b lid domain. Interestingly, it has been
suggested that the C-terminal domain of STNAT is involved in
overall protein stability [39]. A comparison of the intrinsic
stability of human NAT1 and human NAT2 showed that the
C-terminal domain was involved in the diﬀerence in protein
stability between these two NAT paralogs [37]. We carried
out molecular dynamics experiments (2 ns simulations) using
the MLNAT1 structure determined by crystallography and
the MLNAT2 model (Fig. 7). The results shown in Fig. 7 sug-
gest that the a/b lid domain of MLNAT2 is probably more
ﬂexible/mobile than its counterpart in MLNAT1. Indeed, com-
pared to MLNAT1, most of the amino acids in the a/b lid of
MLNAT2 had a RMSF above 1 A˚ (Fig. 7). RMSD variations
(Fig. 7, insets) over time (ps) indicated no signiﬁcant diﬀerence
in the overall structure of MLNAT1 and MLNAT2 at the
beginning and end of the dynamics simulation. Nevertheless,
further analysis (Fig. 8) of the structural behavior of the three
domains (a-bundle, b-barrel and a/b lid) of MLNAT1 and
MLNAT2 over the dynamics simulations clearly showed that
the MLNAT2 a/b lid domain was more ﬂexible/mobile (as re-
ﬂected by higher RMSD values) than the other two structural
domains of MLNAT2. In addition, the three structural do-
mains of MLNAT1 and the two ﬁrst structural domains (a-
bundle and b-barrel domains) of MLNAT2 had similar, fairly
constant RMSD values (around 0.1–0.2 A˚) over the simula-
tions, whereas the a/b lid domain of MLNAT2 had higher
RMSD values (around 0.2–0.4 A˚). Moreover, whereas the sec-
ondary structures of the three structural domains of MLNAT1
remained very stable throughout the molecular dynamics sim-
ulations, stability was observed only for the a-bundle and b-
barrel domains of MLNAT2. Indeed, small variations in the
secondary structure of the a/b lid of MLNAT2 were observed
during the simulations (data not shown). These variations were
mostly observed for certain b-strands of the a/b lid domain of
MLNAT2 and suggest that the b-strands of the a/b lid domain
of MLNAT2 are less stable than those of MLNAT1. Overall,
the molecular dynamics data suggest that diﬀerences in the
structural ﬂexibility/dynamics of the a/b lid domain of
MLNAT2 and MLNAT1 may contribute to the higher intrin-
sic instability of the MLNAT2 isoform. Our results are fully
consistent with data obtained for the two human NAT iso-
forms, indicating that the amino-acid sequence determinants
of the a/b lid domain are involved in determining the overall
intrinsic stability of these two enzymes [37].3.3. Conclusions
The data reported here clearly suggest that, despite their low
percentage sequence identity, the paralogous MLNAT1 and
MLNAT2 enzymes share an identical and typical NAT fold.
In addition, our results suggest that the lower intrinsic stability
of MLNAT2 than of MLNAT1 and the other NAT enzymes
for which crystallographic structures are available may be at
least partly due to diﬀerences in amino-acid sequence/struc-
tural features in the a/b lid domain. Our results show that
the a/b lid domain of NAT enzymes is involved in the overall
intrinsic stability of the protein, as suggested for human iso-
forms [37]. It has also been shown that although MLNAT1and MLNAT2 acetylate the same range of substrates,
MLNAT1 is 70–400 times more active than MLNAT2 for
these substrates [23]. As the C-terminal a/b lid domain of
NAT enzymes is known to be involved in arylamine binding
[15,17], the results reported here for MLNAT2 and its C-termi-
nal a/b lid structure may account for diﬀerences in the behav-
ior of MLNAT1 and MLNAT2 towards substrates. Further
studies are required to address this issue.
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